Phimosis: A rare complication of immunotherapy with durvalumab

Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed?

PDF) Phimosis: A rare complication of immunotherapy with durvalumab

Breakdown of phimosis referrals

Luis Guillermo LLORENTE PETERS, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, INNSZ, Immunology & Rheumatology

5167 PDFs Review articles in FORESKIN

ANZUP's A little below the belt magazine July 2021 by ANZUP Cancer Trials Group - Issuu

Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer

5167 PDFs Review articles in FORESKIN

5167 PDFs Review articles in FORESKIN

Full article: A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape

Ipilimumab (Yervoy) Drug Information

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial - The Lancet Oncology